2[1]Jacobson TA, Schein JR, Williamson A, et al. Mazximizing the cost - effectiveness of lipid - lowering therapy[J ]. Arch Intem Med, 1998,158:1977 - 1989
3[2]Pedersen TR. Coronary artery disease:the Scandinavian Simvastatin Survival Study experience[J]. Am J Cardiol, 1998,82(10) :53 - 56
4[4]Pasterkamp G, Schoneveld AH, Van der Wal AC, et al.Inflammation of the atherosclerotic cap and shoulder of the plaque is a conmom and locally observed feature in unruptured plaques of femoral and coronary arteries[J ]. Arterioscler ThrombVasc Biol, 1999,19: 54 - 58
5[5]Crisby M, Nordin- Fresriksson G, Shah PK, et al.Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization [ J ]. Circulation,2001,2:181 - 188
6Fuster V, Badimon L Badimon JJ, et al. The patho - genesis of coronary artery disease and the acute coronary syndromes (first of two aprts). N Engl J Med, 1992; 326(4) :242 ～ 250
7Davies MJ.The role of plagne pathology in coronary thrombosis. Clin Cardiol,1997;20(Cuppl I): Ⅰ 2
10Kleiman NS.Primary and secondary safety endplints from IMPACT Ⅱ . Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol, 1997; 80(4A): 29B
